Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hendrik Everaert
Patterns of Response in Patients With Pretreated Metastatic Melanoma Who Received Ipilimumab 3 Mg/Kg in a European Expanded Access Program: Five Illustrative Case Reports
Cancer Investigation
Medicine
Cancer Research
Oncology
Related publications
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 Mg/Kg Plus Ipilimumab 3 Mg/Kg Expansion Cohort Results
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Treatment Patterns of Metastatic Melanoma in Five European Countries
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma
Cancer immunology research
Cancer Research
Immunology
E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 Mg/Kg Alone or in Combination With High Dose Interferon-Α2b in Advanced Melanoma
Clinical Cancer Research
Cancer Research
Oncology
Panhypopituitarism in Metastatic Melanoma Patient Treated With Ipilimumab and Pembrolizumab
Journal of Cutaneous Immunology and Allergy
Scalp Melanoma Treated With Ipilimumab in Elderly Patient: A Complete Response to Treatment—Case Report
Journal of Pharmacy and Pharmacology
Site‐specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients With Melanoma Treated With Ipilimumab Combined With Anti–PD‐1 Therapy
Cancer
Cancer Research
Oncology
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated With Ipilimumab
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Corrigendum: Association of CTLA-4 Gene Variants With Response to Therapy and Long-Term Survival in Metastatic Melanoma Patients Treated With Ipilimumab: An Italian Melanoma Intergroup Study
Frontiers in Immunology
Allergy
Immunology
